Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease (CKD) is a growing, global health epidemic that places an enormous social and economic burden on patients, their families, and society.  CKD is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. The impact of CKD is amplified by the fact that It is not one disease, but encompasses several diseases, each with distinct causes.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch Bio is uniquely positioned to translate these discoveries into new therapies that target the molecular causes for diseases of the kidney.


The burden of kidney disease for patients and society





Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.


Anthony Johnson, M.D.

Chief Executive Officer

Michael Broxson

Chief Business and Operating Officer

Frank S. Czerwiec, M.D., Ph.D.

Chief Medical Officer

Peter Mundel, M.D.

Chief Scientific Officer

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Lori Rudolph-Owen, Ph.D.

Senior Vice President, R&D Strategy and Operations

Thomas Tibbitts, Ph.D.

Senior Vice President of Computational Discovery

Curtis Demick

Vice President of Human Resources

John F. Reilly, Ph.D.

Vice President of Biology

Liron Walsh, M.D.

Vice President of Translational and Clinical Nephrology


Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Peter Mundel, M.D.

Goldfinch Bio

Stefan Somlo, M.D.

Yale School of Medicine


Abbie Celniker, Ph.D.

Chairwoman of Goldfinch Bio and Partner, Third Rock Ventures

Louis Brenner, M.D.

President and Chief Executive Officer, Allena Pharmaceuticals

Neil Exter

Partner, Third Rock Ventures

Anthony Johnson, M.D.

Chief Executive Officer

Frank W. Maddux, M.D., F.A.C.P.

Executive Vice President and Chief Medical Officer, Fresenius Medical Care North America





Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates in the right patient subsets. This is achieved by applying a precision medicine approach to selecting patients most suitable for a given therapy.

The cornerstones of Goldfinch’s Product Engine

Kidney Genome AtlasTM

Goldfinch’s Kidney Genome AtlasTM represents the most comprehensive patient registry to investigate the underlying mechanisms of kidney disease. Through the combination of genomic, transcriptomic, and proteomic data with thousands of anonymized clinical patient profiles, Goldfinch has conducted unprecedented analyses to elucidate pathways and novel targets for kidney disease.

Biology Platform

Goldfinch is harnessing advances in stem cell science to develop and apply human organoid models to validate novel targets



Goldfinch’s Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to:

1.     Identify, validate, and pursue novel therapeutic targets for kidney disease

Goldfinch’s Kidney Genome Atlas is integrating genomic, transcriptomic, and proteomic data with clinical data for thousands of patients to discover and identify novel pathways and therapeutic targets for kidney disease. The candidate targets are then validated using Goldfinch’s Biology platform of patient-derived cellular assays and organoid models

2.     Predict and subset patients likely to respond to treatments

Goldfinch is leveraging the Kidney Genome Atlas to select and stratify patients based on molecular signatures and markers of treatment response, enabling a precision medicine approach to clinical development

3.     Provide the molecular rationale to identify and treat relevant subgroups among the broader population of patients with kidney disease

Goldfinch’s product engine will enable therapeutic intervention at key nodes and pathways implicated in kidney dysfunction, with the potential to identify and treat subgroups of patients with broader forms of kidney disease





Goldfinch’s pipeline of therapeutic programs is underscored by strong genetic validation and a deep familiarity with the biological pathways that cause disease. Our initial efforts are focused on focal segmental glomerulosclerosis (FSGS), diabetic nephropathy (DN) and polycystic kidney disease (PKD).


GFB-887 is a TRPC5 ion channel inhibitor in development for the treatment of FSGS.

TRPC5 is a calcium-permeable ion channel that has been implicated in the pathogenesis of FSGS by triggering a Rac1-TRPC5 disease pathway. TRPC5 represents a target for therapeutic intervention to halt progression of FSGS to kidney failure.


Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder and histopathologic diagnosis characterized by severe scarring of the kidney's filtering units, or glomeruli, leading to proteinuria, an excess of essential proteins spilling into the urine.

FSGS is associated with the injury and loss of podocytes, terminally differentiated cells of the kidney glomeruli essential for filtration and proper kidney function. Recent research into the genetics of kidney disease has identified over 30 genes associated with FSGS, and implicates   the podocyte as a central player in the pathogenesis of FSGS.

There are currently no FDA approved treatments for FSGS. Existing treatments are non-specific, do not alter the progression of disease and carry significant toxicities.

Goldfinch is leading the charge to develop treatments targeting the molecular causes of FSGS to drastically improve the lives of patients suffering from this devastating, life-shortening condition.


Diabetic Nephropathy (DN) is the most common cause of chronic kidney disease, and affects roughly 40% of patients with kidney disease.

DN is the most frequent cause of end-stage renal disease worldwide, and is associated with an increased risk of heart attack, stroke and premature death.

Importantly, it may be possible to use Goldfinch Bio’s genetic and precision medicine approach to segment DN and demonstrate effective therapeutics for subgroups of this disorder.


Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide.

The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

Patients with PKD develop fluid filled cysts in the kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age.

In the United States alone, 1 in 20 individuals either on dialysis or with a kidney transplant has PKD.

Goldfinch is leveraging scientific discoveries based on the known genes that cause PKD to discover treatments that may alter the course of PKD and drastically improve the lives of patients suffering from this chronic and debilitating disorder.





It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. 

Goldfinch Bio has built the Kidney Genome Atlas, the world’s largest genomic registry of patients with kidney disease to inform new disease targets, pathways, and biomarkers for the discovery and development of novel therapies.


Kidney Genome Atlas Collaborators

In collaboration with premier academic and clinical institutions, Goldfinch has generated genomic, transcriptomic, and proteomic data on thousands of patients with proteinuric kidney disorders, and is pairing the data with clinical records to gain new insights into the genetic underpinnings of kidney disease.







At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.

Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist.

We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

If this sounds like the community you want to grow with, we invite you to explore our current career opportunities below.


Note to Recruitment Agencies: Please do not forward any agency resumes. Goldfinch Bio is not responsible for any fees related to resumes that are unsolicited.
Equal Opportunity Employer M/F/D/V.